A Phase 4 interventional study of Rivaroxaban 2.5 Mg Oral Tablet and Colchicine 0.5 MG in Ischemic Stroke, sponsored by Brazilian Clinical Research Institute. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Brazilian Clinical Research Institute · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing rivaroxaban in Ischemic Stroke — 4 open to participants now, 4 under way, 2 of them phase 3. Rivaroxaban · Ischemic Stroke.
Among the 10 studies testing rivaroxaban in Ischemic Stroke, this one is the 3rd largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 4, and was the 8th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →4 of the 10 studies testing rivaroxaban in Ischemic Stroke are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
Population Health Research Institute
Ages 40+
The First Affiliated Hospital with Nanjing Medical University
Ages 30–75
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 5 · Phase 4 2
First in 2013; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 1,597 across the 10 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 9 most frequent:
Brazilian Clinical Research Institute is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Brazilian Clinical Research Institute has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing rivaroxaban in Ischemic Stroke, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.
In patients with ischemic stroke, within 14 days of symptom onset, to establish the efficacy and safety of two strategies in parallel: low-dose rivaroxaban and low-dose colchicine, compared with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rivaroxaban 2.5 mg Twice a day (BID) + colchicine 0.5 mg once daily (QD)
Drug: Rivaroxaban 2.5 Mg Oral Tablet · Drug: Colchicine 0.5 MG
rivaroxaban 2.5 mg BID + colchicine placebo QD
Drug: Rivaroxaban 2.5 Mg Oral Tablet · Drug: Placebo Colchicine
rivaroxaban placebo BID + colchicine 0.5 mg QD
Drug: Colchicine 0.5 MG · Drug: Placebo Rivaroxaban
rivaroxaban placebo BID + colchicine placebo QD
Drug: Placebo Rivaroxaban · Drug: Placebo Colchicine
Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
Also known as: Xarelto
Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
Also known as: Colchis
Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.
Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.
Primary efficacy endpoint: Time to cardiovascular death, stroke, myocardial infarction (MI), or urgent arterial
Time to cardiovascular death, stroke, myocardial infarction (MI), or urgent arterial revascularization
Time frame: 12 months
Primary safety endpoint (rivaroxaban versus placebo): Time to major bleeding according to the International Society of Thrombosis and Hemostasis classification
Time to major bleeding according to the International Society of Thrombosis and Hemostasis classification
Time frame: 12 months
Primary safety endpoint (colchicine versus placebo): Hospitalization for respiratory infections
Time to first hospitalization for respiratory infections
Time frame: 12 months
Time to fatal or non-fatal stroke
Time to fatal or non-fatal stroke
Time frame: 12 months
Time to CV death, MI, or stroke
Time to CV death, MI, or stroke
Time frame: 12 months
Time to death from all causes, MI, or stroke
Time to death from all causes, MI, or stroke
Time frame: 12 months
Time to fatal or non-fatal stroke, death, or transient ischemic attack
Time to fatal or non-fatal stroke, death, or transient ischemic attack
Time frame: 12 months
Net clinical endpoint: time to CV death, MI, stroke, fatal bleeding, or critical site bleeding
Time to CV death, MI, stroke, fatal bleeding, or critical site bleeding
Time frame: 12 months
Time to all-cause death
Time to all-cause death
Time frame: 12 months
modified Rankin score
modified Rankin score as ordinal outcome
Time frame: 12 months
Venous thromboembolism
Time to first venous thromboembolism
Time frame: 12 months
New-onset atrial fibrillation
time to new-onset atrial fibrillation
Time frame: 12 months
Microvascular obstruction at head MRI (substudy)
Microvascular obstruction at head MRI (substudy)
Time frame: 12 months
No study locations are listed for this record.
Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 12 months is below that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Jul 2026 → Jan 2027, primary completion Aug 2027 → Jan 2028 and completion Dec 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Colchicine
Brazilian Clinical Research Institute